D. E. Shaw & Co., Inc. Biomea Fusion, Inc. Transaction History

D. E. Shaw & Co., Inc.

$100 Billion
Q1 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 45,238 shares of BMEA stock, worth $71,476. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,238

Previous 116,653 61.22%

Holding current value

$71,476

Previous $452,000 78.76%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$2.13 - $4.48 $152,113 - $319,939	-71,415 Reduced 61.22%	45,238 $96,000
Q4 2024 Feb 14, 2025	BUY	$3.88 - $12.41 $452,613 - $1.45 Million	116,653 New	116,653 $452,000
Q4 2023 Feb 14, 2024	BUY	$8.37 - $19.8 $443,559 - $1.05 Million	52,994 New	52,994 $769,000
Q2 2023 Aug 14, 2023	SELL	$21.66 - $41.8 $3.08 Million - $5.94 Million	-142,008 Reduced 65.26%	75,579 $1.66 Million
Q1 2023 May 15, 2023	BUY	$6.8 - $32.35 $928,839 - $4.42 Million	136,594 Added 168.65%	217,587 $6.75 Million
Q4 2022 Feb 14, 2023	BUY	$6.3 - $11.6 $18,339 - $33,767	2,911 Added 3.73%	80,993 $682,000
Q3 2022 Nov 14, 2022	BUY	$9.51 - $13.61 $543,658 - $778,042	57,167 Added 273.33%	78,082 $764,000
Q2 2022 Aug 15, 2022	BUY	$3.0 - $12.03 $62,745 - $251,607	20,915 New	20,915 $251,000
Q1 2022 May 16, 2022	SELL	$4.39 - $9.03 $91,992 - $189,223	-20,955 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.22 - $12.72 $151,295 - $266,547	20,955 New	20,955 $156,000

Others Institutions Holding BMEA

# of Institutions

106

Shares Held

15.8M

Call Options Held

229K

Put Options Held

354K

View Full List

About Biomea Fusion, Inc.

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $46.3M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

More about BMEA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account